Table 2 Included studies with their major findings
Author (year) | Target population age range (Children) | Study place | Sample size | Clinical success %Azithromycin/amoxicillin-clavulanate | P-value (95% CI) |
|---|---|---|---|---|---|
Daniel (1993) | (2–8 year) with OM | Europe Multi center | 159 | 99%/100% | NS (N/A) |
Schaad (1993) | 6 months to 12 years with AOM | Switzerland | 389 | 93.2%/97.4% | NS (N/A) |
Principi (1995) | (6-months to 12 years) with OM | Brazil, Chile, Germany, Italy, Korea, Spain, Turkey Venezuela | 483 | 92.6%/93.9%) | NS (N/A) |
Arguedasa et al. (1996) | 6-months to 12 years with OM with effusion | San Jose Costa Rica | 100 | 82.5%/78.9%) | NS (N/A) |
Gerson (1996) | 2 to 15 years with Acute otitis media | USA | 169 | 87.7%/100% | 0.102 (N/A) |
Mohini (1996) | (6-months to 12 years) with Acute otitis media | USA | 527 | 92.3%/90% | 0.417 (N/A) |
Samuel (1996) | 1 to 15 years with AOM | USA | 677 | 87.6%/87.9% | 0.636 (N/A) |
Dagan (2000) | 6 months to 2 years with AOM | Israel USA and Dominican Republic | 238 | 70% / 85.7% | 0.023 (2,30) |
Arrieta et al. (2003) | 6-months to 6 years with recurrent or persistent AOM | USA, Latin American centers | 304 | 85.9%/84.1%) | 0.744 (− 6.4, 10) |
Block et al. (2003) | (6-months to 12 years) with AOM | USA | 350 | 86.9%/87.7% | NS (− 9.2, 6.5) |
Dune et al. (2003) | (6-months to 12 years) with AOM | USA | 373 | 82.7%/88.3% | 0.186 (− 13, 3) |
Hoberman et al. (2005) | 6 month to 30 month with AOM | USA. Bulgaria, Chile, Domenica Republic, Guatemala, Israel, Peru, Romania Latvia Mexico, | 731 | 80.9%/90.5% | < 0.01 (2.37,17) |
Guven et al. (2006) | (6-months to 12 years) with AOM | Turkey | 180 | 100%/100% | 0.24 (N/A) |
Arguedas et al (2011) | 3 months–4 years with AOM | North America, Europe, and Latin America | 923 | 80.2%/84.5% | 0.24 (− 10.4, 2.6) |